Generer rapport
Immudex Aps
Bredevej 2A, 2830 Virum, CVR 31348854
Virksomhedsform
Anpartsselskab
Etableret
2008
Størrelse
Små
Ansatte
39
Omsætning
-
DKK
Bruttofortj.
30
MDKK
Primært resultat (EBIT)
-1.488.884
DKK
Årets resultat
-1.092.079
DKK
Egenkapital
30
MDKK
annonce
Flere nøgletal og analyser?
Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!
Rang Årets resultat
Rang i branche
258/360
"Bund 35%"
Rang i Danmark
324.982/344.121
"Bund 10%"
Direktion top 3
| Patrik Olof Dahlén 7 | CEO |
Bestyrelse top 3
| Søren Elmann Ingerslev 40 | Bestyrelsesformand |
| Douglas Frank Sweet 1 | Bestyrelsesmedlem |
| Helene Kähler Hjenner 16 | Bestyrelsesmedlem |
Legale ejere top 3
| 50-66.66% | Viggo Harboe 2006 Holding Aps | DK |
| 20-24.99% | Gunnersen Marker Holding Aps | DK |
| 5-9.99% | Hjeca Holding I Aps | DK |
Tegningsregler
Selskabet tegnes af en direktør i forening med bestyrelsens formand eller af to bestyrelsesmedlemmer i forening.
Stamoplysninger baseret på CVR
| Navn | Immudex Aps |
| CVR | 31348854 |
| Adresse | Bredevej 2A, 2830 Virum |
| Branche | Forskning og eksperimentel udvikling indenfor bioteknologi [721100] |
| Web | www.immudex.com |
| Etableret | 01-04-2008 (16 år) |
| Første regnskabsperiode | 01-04-2008 til 30-06-2009 |
| Virksomhedsform | Anpartsselskab |
| Antal ansatte | 47 (årsværk:45) |
| Reklamebeskyttelse | Nej |
| Revisor | Powered-By Statsautoriseret Revisionspartnerselskab siden 27-11-2023 |
| Regnskabsperiode | 01-07 til 30-06 |
| Selskabskapital | 725.927 DKK 711.505 DKK (08-03-2023 - 30-01-2024) 700.136 DKK (08-04-2022 - 07-03-2023) 688.667 DKK (18-06-2020 - 07-04-2022) 536.124 DKK (26-01-2017 - 17-06-2020) 479.340 DKK (09-11-2015 - 25-01-2017) |
| Vedtægter seneste | 31-01-2024 |
Medlem af brancherne
- Forskning og eksperimentel udvikling indenfor bioteknologiNACE6 indeholdende 556 virk.
- Forskning og eksperimentel udvikling indenfor naturvidenskab og teknikNACE3 indeholdende 1.769 virk.
- Videnskabelig forskning og udviklingNACE2 indeholdende 2.061 virk.
- Liberale, videnskabelige og tekniske tjenesteydelserNACE1 indeholdende 86.838 virk.
Formål
Selskabets formål er kommercialisering af immunmonitorerings metoder
Regnskab
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Valuta/enhed | 000' DKK | 000' DKK | 000' DKK |
| Omsætning | - - | - - | - - |
| Bruttofortjeneste | 29.872 +58% | 18.938 -22% | 24.389 +60% |
| Årets resultat | -1.092 - | -6.769 - | 754 - |
| Egenkapital | 29.924 +2% | 29.376 -15% | 34.451 +2% |
| Balance | 42.449 +3% | 41.060 -12% | 46.841 +2% |
Ledelsesberetning
Development in activities and financesThe Company has during the fiscal year had the following focus areas:
i. Increase sales of RUO (research-use-only) Dextramer® reagents
ii. Increase sales of clinical-grade Dextramer (GMP) reagents to biophama companies engaged in T-cell therapy development
iii. Increase output of new products and services by investing in more R&D activities
iv. Expand commercial activities
The total sales revenue at group level of RUO/GMP/IVD reagents increased by 18% relative to the previous fiscal year with approximately 54% of the sales in North America and 46% in the rest of the world.
Immudex continued to invest significant resources in 1) the development of new Dextramer® reagents, 2) in expanding commercial activities and 3) maintaining and protecting existing patent portfolio.
The Company has realized a loss of DKK 1.1 million. A loss was planned related to higher staff costs due to the increase in the number of employees and related activities.
The loss is affected by the capitalization of the development costs in 2022/23. The company has changed accounting policies for 2022/23 so that the development costs is now recognized in the balance sheet. The change of the accounting policies has resulted in a reduction of the loss with 2.2 million cf. also mentioned under accounting policies.
i. Increase sales of RUO (research-use-only) Dextramer® reagents
ii. Increase sales of clinical-grade Dextramer (GMP) reagents to biophama companies engaged in T-cell therapy development
iii. Increase output of new products and services by investing in more R&D activities
iv. Expand commercial activities
The total sales revenue at group level of RUO/GMP/IVD reagents increased by 18% relative to the previous fiscal year with approximately 54% of the sales in North America and 46% in the rest of the world.
Immudex continued to invest significant resources in 1) the development of new Dextramer® reagents, 2) in expanding commercial activities and 3) maintaining and protecting existing patent portfolio.
The Company has realized a loss of DKK 1.1 million. A loss was planned related to higher staff costs due to the increase in the number of employees and related activities.
The loss is affected by the capitalization of the development costs in 2022/23. The company has changed accounting policies for 2022/23 so that the development costs is now recognized in the balance sheet. The change of the accounting policies has resulted in a reduction of the loss with 2.2 million cf. also mentioned under accounting policies.
27-11-2023